Kissei Pharmaceutical, Amgen's Japanese partner, has advised doctors to exercise caution when prescribing Tavneos (avacopan) due to safety concerns, including risks of liver dysfunction. This follows FDA warnings and a proposed withdrawal of Tavneos approval in the U.S. over data integrity issues and questionable effectiveness. In Japan, 20 deaths have been reported among Tavneos users, though causality is unclear. Kissei is coordinating with health authorities in Japan, the U.S., and Europe to ensure patient safety while the drug remains approved in Japan.
The oligonucleotide drug development pipeline is rapidly expanding, featuring over 600 candidates from more than 200 companies including Novartis, Amgen, and Alnylam. These therapies target genetic diseases, cancers, and rare disorders using advanced...
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
